In addition, Kletting et al. used a PBPK model to individually predict tumor response after radioligand therapy (based on pre-therapeutic imaging) using [177Lu]Lu-PSMA I&T in metastatic castration resistant prostate cancer patients 48. Here, FOLH1 is linked to prostate carcinoma.